Stock Market Review – 4/15 – 4/19

Markets continued to fall this week, with the Nasdaq suffering the biggest losses. Analysts are adjusting ratings as they assume interest rate cuts won’t happen until the fall, perhaps as early as 2025.

Geopolitical concerns are also on investors’ minds. The reason is the impact they have on oil prices. If oil prices were to rise, this would directly affect inflation, which is already expected to rise in the coming months.

But in the coming weeks everything will depend on profits and, more importantly, on the indications that companies provide. Next week, earnings season will come into full swing as investors begin to learn about some of the Big 7 stocks of 2023. MarketBeat analysts will be tracking all of these reports. In the meantime, here are some of our most popular stories this week.

Articles by Jea Yu

Novo Nordisk AV/S NYSE: NVO the stock soared along with the success of the drugs Ozempic and Wegovy. Currently, these GLB-1 treatments can only be prescribed for diabetes or obesity, respectively. The stock retired recently. However, Jea Yu explained that NVO’s stock could take a jolt as the company is testing the drug for other indications that include “obesity-related pulmonary and cardiovascular diseases and potentially neurological disorders.”

Gold has been one of the best performing asset classes in 2024. However, silver has not seen the same gains, at least not yet. Yu wrote about two silver stocks that are starting to move higher, as the underlying commodity is still well below its all-time high.

And this week, Yu explained how options traders can use a credit put spread as an alternative to a debit spread when they believe a stock will go up but want to limit downside risk. This article details how a put credit spread works and the pros and cons of using the strategy.

Articles by Thomas Hughes

Money continues to flow into energy stocks due to the reality of limited supply and accelerating demand. This week, Thomas Hughes offers investors three energy stocks that pay dividends, buy back shares and offer the potential for long-term share price gains.

Hughes was also writing about ‘s recent earnings report UnitedHealth Group Inc. NYSE: UNH. The stock is up 12%, ending a five-month slump that had sent the stock to nearly 12-month lows. Hughes explains the reasons, beyond the headline-grabbing numbers, why UNH stock won’t be undervalued for much longer.

Another stock that might be as cheap as possible is Johnson & Johnson NYSE:JNJ. Hughes explains why the slimmed down company’s latest earnings report was bullish in many of the ways that should matter most and could put the stock in a buy point for investors.

Articles by Sam Quirke

Many companies went public in 2021 with great fanfare that has since seen shares fall 50% or more. One of these titles was GitLab Inc. NASDAQ: GTLB. After hitting bottom last May, GTLB stock is in rally mode. However, weak guidance has triggered a sell-off that Sam Quirke believes there is 40% upside for GTLB stock.

DocuSign Inc. NASDAQ: DOCU went public shortly before GitLab, but DOCU shares have also fallen sharply from their 2021 high. After a 60% rally since November 2023, Quirke argues for a stock upside of up to 66%.

Quirke also explains the relative strength indicator (RSI) and how that technical indicator helps direct investors towards overbought or oversold stocks and provides three stocks with oversold indicators.

Articles by Ryan Hasson

Next week, investors will get their first read on several Magnificent Seven stocks. Many of these titles have lost their luster. However, Ryan Hasson wrote about three Magnificent 7 stocks that are still outperforming their Mag 7 counterparts and the broader market.

Hasson is also looking at energy stocks. He was specifically analyzing five small-cap energy stocks that have recently shown strong price and volume movements and may have further upside in store for investors.

AND Tesla Inc. NASDAQ:TSLA there will be a closely watched earnings report next week. The company’s results have become a bellwether for many technology stocks. Before the company reports, read Quirke’s article to understand all the factors weighing on the stock and what investors should pay attention to when the company reports.

Articles by Gabriel Osorio-Mazilli

As you can see, there are good reasons why MarketBeat analysts are focused on energy stocks. This week, Gabriel Osorio-Mazilli explains why Kinder Morgan Inc. New York Stock Exchange: KMI is a solid midstream company that analysts say shows double-digit upside stemming from increased demand for oil and natural gas.

Steel stocks took center stage this week after President Biden launched a 30% tariff on Chinese steel. It is appropriate, then, that Osorio-Mazilli offers three steel stocks positioned to benefit from the imposition of such tariffs.

And stocks remain in focus. This week Osorio-Mazilli explains why ASML company NASDAQ:ASML it could be a solid way to invest in the sector as the next leg of the semiconductor stock rally is underway.

Before you consider Novo Nordisk A/S, you’ll want to hear this.

MarketBeat tracks daily Wall Street’s highest-rated and best-performing research analysts and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market takes hold… and Novo Nordisk A/S wasn’t on the list.

While Novo Nordisk A/S currently has a “Moderate Buy” rating among analysts, top analysts believe these five stocks are better buys.

View the five stocks here